Skip to main content

Table 15 Selected phase I clinical trials conducted with MIK655 or S64315 as a single (S) therapeutic, on untreated, and refractory (Refrac) diseases, such as Multiple Myeloma (MM), Diffuse Large Cell B-Lymphoma (DLBCL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (AST) patients, for Maximum Tolerated Dose (MTD) are highlighted. Adverse effects (Adv. Effects) are highlighted as Nausea (Nau), Familial Neutropenia (F-Neut) and Diarrhoea (Diar). The clinical trials reference numbers are highlighted in bold (left column) and the Objective Response Rates (ORR) expressed as the percentage of patients who responded positively (%). Unavailable data is highlighted by ‘-‘

From: BH3-mimetics: recent developments in cancer therapy

MIK655/S64315 Phase Single Patients Refrac Disease Outcomes Adv. Effects ORR
NCT02992483 I S Untreated Yes MM, DLBCL MTD Unpublished
NCT02979366 I S Untreated (14 days) Yes AML, MDS MTD Nau/F-Neut/Diar 0% ORR